NON-HODGKIN LYMPHOMA

O038 - CD19/CD22 DUAL TARGETED (CHIMERIC ANTIGEN RECEPTOR) CAR-T THERAPY FOR RELAPSED OR RE FRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)

Houli Zhao, Yongxian Hu, Arnon Nagler, et al.

Conclusions: CD19/CD22 dual targeted CAR-T is a promising solution for improving response and prolonging PFS for r/r B-NHL patients with less than grade 3 CRS adverse events. Cytokine profiling showed CD40 ligand, MIP-1β, GROβ, EGF, PDGF-AB/BB, RANTES, IL-8, TRAIL decrease and PD-L1/B7-H1, MIP-1α, GM-CSF, IL-1ra, IL-3, IL-5, MIP-3β, MCP-1, IP-10 increase during CRS. MIP-3β may be a biomarker of early phase of CRS. Lower level of CD40 ligand, FGF basic at early phase of CRS and lower level of GM-CSF, IP-10 when recovery from CRS may be related to good response.

 

O041 - OUTPATIENT TREATMENT WITH LISOCABTAGENE MARALEUCEL IN 3 CLINICAL STUDIES OF RELAPSED/REFRACTORY LARGE B-CELL NHL, INCLUDING SECOND-LINE TRANSPLANT NONELIGIBLE PATIENTS: TRANSCEND NHL 001, OUTREACH, AND PILOT

Carlos Bachier, M. Lia Palomba, Jeremy Abramson, et al.

Conclusions: A subset of patients with relapsed/refractory large B-cell NHL were successfully treated with liso-cel and monitored for CAR T cell-related toxicity in the outpatient setting, including elderly patients and patients with high tumor burden. Incidences of severe CRS, NEs, and early hospitalization were low; 45% of patients did not require hospitalization at any time after liso-cel infusion. Overall, 80% of patients achieved an objective response.

 

A092 - REAL-WORLD DATA FROM KINGS COLLEGE HOSPITAL: INFECTION COMPLICATIONS POST CAR-T TREATMENT IN HIGH-GRADE B CELL NON-HODGKIN LYMPHOMA

Shu Min Wong, Mili Shah, Shafqat Inam, et al.

Conclusions: In our cohort most patients treated with CAR-T cells did not appear to have an increased risk of early or late infections and this is despite CRS and administration of tocilizumab and steroids. There was 1 patient who had significant infections post CAR-T likely due to persistent neutropenia and lymphopenia and another who died of late sepsis. Despite significant B cell aplasia pre and post CAR-T the immunoglobulin levels in most patients remained >4g/L which suggests that the humoral immune system can remain intact despite B cell aplasia. Immunoglobulin levels will be correlated with 6-month outcomes in final analysis.

 

A098 - CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOLLOWED BY HEMATOPOIETIC STEM CELL TRANSPLANTATION MAY IMPROVE PROGRESSION FREE SURVIVAL IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

H. Huang S. Liu Q. Zhu Y. Duan D. Wu

Conclusions: Hematopoietic stem cell transplantation(HSCT) appear to improve progression-free survival (PFS) for the patients achieving remission following CAR-T therapy with relapse/refractory B-cell lymphoma. Future prospective studies needed to clearly define the role of consolidative HSCT in the relapse/refractory B-cell lymphoma patients who attained remission from CAR-T infusion and importantly, better identify this strategy whether exhibits superior overall survival outcomes.